Cargando…

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

BACKGROUND: A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Feng-Cai, Li, Yu-Hua, Guan, Xu-Hua, Hou, Li-Hua, Wang, Wen-Juan, Li, Jing-Xin, Wu, Shi-Po, Wang, Bu-Sen, Wang, Zhao, Wang, Lei, Jia, Si-Yue, Jiang, Hu-Dachuan, Wang, Ling, Jiang, Tao, Hu, Yi, Gou, Jin-Bo, Xu, Sha-Bei, Xu, Jun-Jie, Wang, Xue-Wen, Wang, Wei, Chen, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255193/ https://www.ncbi.nlm.nih.gov/pubmed/32450106 http://dx.doi.org/10.1016/S0140-6736(20)31208-3

Ejemplares similares

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
por: Zhu, Feng-Cai, et al.
Publicado: (2020)

Newcastle disease virus-vectored West Nile fever vaccine is immunogenic in mammals and poultry
por: Wang, Jinliang, et al.
Publicado: (2016)

Construction and characterization of a recombinant human adenovirus vector expressing bone morphogenetic protein 2
por: ZHANG, ZHENG, et al.
Publicado: (2013)

Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant
por: Jia, Shuo, et al.
Publicado: (2020)

Correction to: Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant
por: Jia, Shuo, et al.
Publicado: (2022)

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
por: Ulaszewska, Marta, et al.
Publicado: (2023)

Immunogenicity of recombinant Lactobacillus plantarum NC8 expressing goose parvovirus VP2 gene in BALB/c mice
por: Liu, Yu-Ying, et al.
Publicado: (2017)

Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer
por: Chen, Ping, et al.
Publicado: (2014)

Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates
por: Zhang, Xuefeng, et al.
Publicado: (2018)

Study of Fusion Protein and Attachment Glycoprotein of Nipah Virus Expressed in Recombinant Baculovirus
por: WANG, Xi-Jun, et al.
Publicado: (2006)

Safety and Immunogenicity of a Recombinant Tetanus Vaccine in Healthy Adults in China: A Randomized, Double‐Blind, Dose Escalation, Placebo‐ and Positive‐Controlled, Phase 1/2 Trial
por: Xu, Xiaowei, et al.
Publicado: (2021)

P17-27. Development of recombinant adenovirus 28 vectors for HIV vaccines
por: Ko, S, et al.
Publicado: (2009)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
por: Folegatti, Pedro M., et al.
Publicado: (2019)

Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients
por: Zhao, Hua, et al.
Publicado: (2018)

Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates
por: Zhang, Xuefeng, et al.
Publicado: (2018)

Suppression effect of recombinant adenovirus vector containing hIL-24 on Hep-2 laryngeal carcinoma cells
por: CHEN, XUEMEI, et al.
Publicado: (2014)

Immunogenicity of a recombinant VSV-Vectored SARS-CoV vaccine induced robust immunity in rhesus monkeys after single-dose immunization
por: Shan, Dan, et al.
Publicado: (2022)

Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity
por: Provine, Nicholas M., et al.
Publicado: (2022)

Construction, expression and antiviral activity analysis of recombinant adenovirus expressing human IFITM3 in vitro
por: Du, Shouwen, et al.
Publicado: (2019)

A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
por: Wu, Shipo, et al.
Publicado: (2020)

Recombinant human adenovirus-p53 therapy for the treatment of nasopharyngeal carcinoma: a meta-analysis
por: Yuan, Cheng, et al.
Publicado: (2016)

Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial
por: Mo, Zhao-Jun, et al.
Publicado: (2023)

Immunogenicity of eGFP-Marked Recombinant Lactobacillus casei against Transmissible Gastroenteritis Virus and Porcine Epidemic Diarrhea Virus
por: Yu, Meiling, et al.
Publicado: (2017)

Recombinant adenovirus vector-mediated human MDA-7 gene transfection suppresses hepatocellular carcinoma growth in a mouse xenograft model()
por: Pan, Xinting, et al.
Publicado: (2012)

Recombination analysis reveals a double recombination event in hepatitis E virus
por: Wang, Hua, et al.
Publicado: (2010)

Evaluation of immunogenicity and protective efficacy of recombinant outer membrane proteins of Haemophilus parasuis serovar 5 in a murine model
por: Li, Miao, et al.
Publicado: (2017)

Immunogenicity Analysis of the Recombinant Plasmodium falciparum Surface-Related Antigen in Mice
por: Yu, Jia-Li, et al.
Publicado: (2022)

Recombinant Expressed Vector pET32a (+) S Constructed by Ligation Independent Cloning
por: Wang, Yu, et al.
Publicado: (2014)

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
por: Jenkin, Daniel, et al.
Publicado: (2022)

Canine Recombinant Adenovirus Vector Induces an Immunogenicity-Related Gene Expression Profile in Skin-Migrated CD11b(+) -Type DCs
por: Contreras, Vanessa, et al.
Publicado: (2012)

Comparative immunogenicity analysis of intradermal versus intramuscular immunization with a recombinant human adenovirus type 5 vaccine against Ebola virus
por: Zhang, Zhe, et al.
Publicado: (2022)

Comparative evaluation of protective immunity against Francisella tularensis induced by subunit or adenovirus-vectored vaccines
por: Zhao, Mengsu, et al.
Publicado: (2023)

Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaque
por: Dai, Xuedong, et al.
Publicado: (2022)

Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine
por: Sayedahmed, Ekramy E., et al.
Publicado: (2023)

Covalent decoration of adenovirus vector capsids with the carbohydrate epitope αGal does not improve vector immunogenicity, but allows to study the in vivo fate of adenovirus immunocomplexes
por: Kratzer, Ramona F., et al.
Publicado: (2017)

A novel recombinant serotype 4 fowl adenovirus expressing fiber-2 protein of duck adenovirus 3
por: Guo, Yiwen, et al.
Publicado: (2023)

Possible Spread of adenovirus type 3 from poultry to humans: indirect evidence from an outbreak in China
por: Bao, Changjun, et al.
Publicado: (2007)

Effective inhibition of cancer cells by recombinant adenovirus expressing EGFR-targeting artificial microRNA and reversed-caspase-3
por: Yan, Maoxiao, et al.
Publicado: (2020)

Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: “Adenovirus Vaccine Within an Adenovirus Vector”
por: Yan, Yuqian, et al.
Publicado: (2020)

A novel and simple method for construction of recombinant adenoviruses
por: Tan, Rong, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_k0o282ta75kr6ujlrs88avbqf4